Fragasso Financial Advisors Inc Lowers Stock Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)

Fragasso Financial Advisors Inc trimmed its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 3.2% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 14,538 shares of the medical research company’s stock after selling 487 shares during the period. Fragasso Financial Advisors Inc’s holdings in Charles River Laboratories International were worth $2,684,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. Wellington Management Group LLP raised its holdings in Charles River Laboratories International by 135,927.9% in the 3rd quarter. Wellington Management Group LLP now owns 3,740,768 shares of the medical research company’s stock worth $736,819,000 after acquiring an additional 3,738,018 shares during the last quarter. State Street Corp raised its holdings in Charles River Laboratories International by 2.0% in the 3rd quarter. State Street Corp now owns 2,130,279 shares of the medical research company’s stock worth $419,601,000 after acquiring an additional 41,421 shares during the last quarter. Kayne Anderson Rudnick Investment Management LLC raised its holdings in Charles River Laboratories International by 1.7% in the 2nd quarter. Kayne Anderson Rudnick Investment Management LLC now owns 1,908,989 shares of the medical research company’s stock worth $394,359,000 after acquiring an additional 31,359 shares during the last quarter. Allspring Global Investments Holdings LLC raised its holdings in Charles River Laboratories International by 40.7% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,760,781 shares of the medical research company’s stock worth $346,821,000 after acquiring an additional 509,163 shares during the last quarter. Finally, Earnest Partners LLC raised its holdings in Charles River Laboratories International by 12.4% in the 2nd quarter. Earnest Partners LLC now owns 1,004,486 shares of the medical research company’s stock worth $207,507,000 after acquiring an additional 110,725 shares during the last quarter. 98.91% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities analysts recently weighed in on CRL shares. Bank of America decreased their price objective on shares of Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating for the company in a report on Friday, December 13th. CLSA lowered shares of Charles River Laboratories International from a “hold” rating to an “underperform” rating and set a $164.00 target price for the company. in a research note on Monday, November 18th. Redburn Atlantic assumed coverage on shares of Charles River Laboratories International in a research note on Monday, October 14th. They set a “sell” rating and a $151.00 target price for the company. StockNews.com lowered shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a research note on Thursday, November 7th. Finally, UBS Group boosted their target price on shares of Charles River Laboratories International from $240.00 to $250.00 and gave the company a “buy” rating in a research note on Thursday, November 7th. Three equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat, Charles River Laboratories International presently has an average rating of “Hold” and a consensus target price of $214.00.

Charles River Laboratories International Price Performance

Shares of NYSE CRL traded up $4.12 during mid-day trading on Monday, hitting $190.24. 272,571 shares of the company’s stock traded hands, compared to its average volume of 574,662. The company has a market capitalization of $9.73 billion, a P/E ratio of 23.81, a PEG ratio of 5.00 and a beta of 1.38. Charles River Laboratories International, Inc. has a 1 year low of $176.48 and a 1 year high of $275.00. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.48 and a quick ratio of 1.14. The company’s 50-day moving average is $193.42 and its two-hundred day moving average is $199.44.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings data on Wednesday, November 6th. The medical research company reported $2.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.43 by $0.16. The business had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $975.99 million. Charles River Laboratories International had a net margin of 10.44% and a return on equity of 14.29%. The firm’s quarterly revenue was down 1.6% compared to the same quarter last year. During the same quarter last year, the firm earned $2.72 earnings per share. On average, equities analysts anticipate that Charles River Laboratories International, Inc. will post 10.18 EPS for the current fiscal year.

Insider Activity

In related news, Director Richard F. Wallman sold 6,621 shares of Charles River Laboratories International stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $216.12, for a total transaction of $1,430,930.52. Following the transaction, the director now directly owns 12,386 shares of the company’s stock, valued at $2,676,862.32. This trade represents a 34.83 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Insiders own 1.30% of the company’s stock.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).